Molecular and cellular characterization of essential human genes.

人类必需基因的分子和细胞特征。

基本信息

  • 批准号:
    10517781
  • 负责人:
  • 金额:
    $ 166.98万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-09-22 至 2027-06-30
  • 项目状态:
    未结题

项目摘要

We propose to generate barcoded and conditional null alleles in a cellular system that can model early human development and a broad range of human diseases. We will establish a data production research and development center in response to the RFA-HG-21-029: Molecular Phenotypes of Null Alleles in Cells (MorPhiC) Phase 1, which aims to establish a catalog of molecular and cellular phenotypes of null alleles for ultimately every human gene, using in vitro multicellular systems. Our center will utilize a chemically inducible and reversible system that enables the rapid depletion of target proteins. The approach permits temporal control of protein levels to study the consequences of null alleles. We will utilize a super sensitive degron that rapidly degrades the target protein of interest in response to a low dose of auxin, a cell membrane diffusible small chemical plant hormone. We will combine CRISPR-based targeted locus engineering to homozygous knock-in a mini auxin-inducible degron (mAID) at the end of the targe gene to create a chemically controllable switch to create null-alleles in an open-access human induced pluripotent stem (hiPSC) cell, which can be differentiated into various cell lineages and multicellular organoids to model human development and diseases. Notably, each AID-degron will also contain gene-specific barcodes, allowing tracking the fate of hundreds of thousands of null alleles when these engineered null alleles are pooled. The proposed approach is generalizable and can rapidly deplete target proteins codded by various classes of human genes. Our strategy will be particularly advantageous and critical to study the null phenotypes of essential genes, which cannot be studied by chronic depletion using genetic approaches (such as CRISPR KO) because the knock-in results in cell death. Therefore, to highlight the utility of our strategy, we prioritize creating null alleles by CRISPR mediated knock-in process to introduce barcoded AID degron in 250 essential genes. We chose genes implicated in human diseases and subviable phenotypes in the International Mouse Phenotyping Consortium (IMPC). We propose to catalog the cellular phenotypes (survival, proliferation, mitotic function, and differentiation) and molecular phonotypes, including gene expression and chromatin accessibility for select null alleles. This information will provide unique insights into the biological function of these developmentally critical genes. It will highlight the utility of establishing the chemically inducible degron system as a generalizable strategy for the goals of the MorPhiC consortium. The created barcoded and conditional null allele resource will provide a unique opportunity to temporally control the timing of null alleles in pluripotent stem state and various terminally differentiated cell types or multicellular organoid systems that can be generated from the pluripotent stem cells.
我们建议生成条形码和条件空

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Mazhar Adli其他文献

Mazhar Adli的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Mazhar Adli', 18)}}的其他基金

Chemo-mediated transcriptional reprogramming in ovarian cancer
卵巢癌中化疗介导的转录重编程
  • 批准号:
    10346704
  • 财政年份:
    2022
  • 资助金额:
    $ 166.98万
  • 项目类别:
Molecular and cellular characterization of essential human genes.
人类必需基因的分子和细胞特征。
  • 批准号:
    10708906
  • 财政年份:
    2022
  • 资助金额:
    $ 166.98万
  • 项目类别:
Chemo-mediated transcriptional reprogramming in ovarian cancer
卵巢癌中化疗介导的转录重编程
  • 批准号:
    10709477
  • 财政年份:
    2022
  • 资助金额:
    $ 166.98万
  • 项目类别:
Identifying the Drivers and Targeting Chemo Resistance in Ovarian Cancer
确定卵巢癌的驱动因素并针对化疗耐药性
  • 批准号:
    10166791
  • 财政年份:
    2017
  • 资助金额:
    $ 166.98万
  • 项目类别:
Identifying the Drivers and Targeting Chemo Resistance in Ovarian Cancer
确定卵巢癌的驱动因素并针对化疗耐药性
  • 批准号:
    9330488
  • 财政年份:
    2017
  • 资助金额:
    $ 166.98万
  • 项目类别:

相似国自然基金

基于MFSD2A调控血迷路屏障跨细胞囊泡转运机制的噪声性听力损失防治研究
  • 批准号:
    82371144
  • 批准年份:
    2023
  • 资助金额:
    49.00 万元
  • 项目类别:
    面上项目
rhTβ4增强间充质干细胞调节T细胞代谢重塑治疗干眼的机制研究
  • 批准号:
    32000530
  • 批准年份:
    2020
  • 资助金额:
    24.0 万元
  • 项目类别:
    青年科学基金项目
胰岛素和细菌信号协同调节巨噬细胞免疫反应的作用
  • 批准号:
    92057105
  • 批准年份:
    2020
  • 资助金额:
    89.0 万元
  • 项目类别:
    重大研究计划
聚谷氨酰胺(PolyQ)疾病致病蛋白构象多态性的研究及应用
  • 批准号:
    31970748
  • 批准年份:
    2019
  • 资助金额:
    60.0 万元
  • 项目类别:
    面上项目
MAPK11通过RNA结合蛋白ELAVL1调控HTT水平的机制与病理意义研究
  • 批准号:
    31970747
  • 批准年份:
    2019
  • 资助金额:
    58.0 万元
  • 项目类别:
    面上项目
细胞代谢重组过程中蛋白质组热稳定性分析
  • 批准号:
    31970706
  • 批准年份:
    2019
  • 资助金额:
    58.0 万元
  • 项目类别:
    面上项目
Atg4B可逆氧化修饰的作用机制及其对自噬的调节研究
  • 批准号:
    31970699
  • 批准年份:
    2019
  • 资助金额:
    50.0 万元
  • 项目类别:
    面上项目
用识别EBV相关淋巴瘤抗原多肽的T细胞受体做转基因免疫治疗
  • 批准号:
    81041002
  • 批准年份:
    2010
  • 资助金额:
    10.0 万元
  • 项目类别:
    专项基金项目
半群代数和半群表示
  • 批准号:
    10961014
  • 批准年份:
    2009
  • 资助金额:
    18.0 万元
  • 项目类别:
    地区科学基金项目
Cellular & Molecular Immunology
  • 批准号:
    30824806
  • 批准年份:
    2008
  • 资助金额:
    20.0 万元
  • 项目类别:
    专项基金项目

相似海外基金

Molecular and functional characterization of type I and II vestibular hair cells in adult mice
成年小鼠 I 型和 II 型前庭毛细胞的分子和功能特征
  • 批准号:
    10749188
  • 财政年份:
    2023
  • 资助金额:
    $ 166.98万
  • 项目类别:
Leveraging Spatial Location for Single-Cell Molecular and Morphological Characterization
利用空间定位进行单细胞分子和形态学表征
  • 批准号:
    10534272
  • 财政年份:
    2023
  • 资助金额:
    $ 166.98万
  • 项目类别:
Molecular, Cellular, and Tissue Characterization Unit
分子、细胞和组织表征单元
  • 批准号:
    10904040
  • 财政年份:
    2023
  • 资助金额:
    $ 166.98万
  • 项目类别:
2/2 Large-scale, single-cell characterization of molecular and cellular networks of mood regulation circuitry in major depressive disorder
2/2 重度抑郁症情绪调节回路的分子和细胞网络的大规模单细胞表征
  • 批准号:
    10745412
  • 财政年份:
    2023
  • 资助金额:
    $ 166.98万
  • 项目类别:
1/2 Large-scale, single-cell characterization of molecular and cellular networks of mood regulation circuitry in major depressive disorder
1/2 重度抑郁症情绪调节回路的分子和细胞网络的大规模单细胞表征
  • 批准号:
    10744931
  • 财政年份:
    2023
  • 资助金额:
    $ 166.98万
  • 项目类别:
Molecular, Cellular, and Tissue Characterization Unit
分子、细胞和组织表征单元
  • 批准号:
    10900845
  • 财政年份:
    2023
  • 资助金额:
    $ 166.98万
  • 项目类别:
A Molecular Case Series: Deep Cellular and Spatial Epigenetic Characterization of Human Colorectal Cancer
分子案例系列:人类结直肠癌的深层细胞和空间表观遗传特征
  • 批准号:
    10537774
  • 财政年份:
    2022
  • 资助金额:
    $ 166.98万
  • 项目类别:
Molecular Characterization Trial of Irradiated Rectal Cancer
辐照直肠癌的分子表征试验
  • 批准号:
    10517806
  • 财政年份:
    2022
  • 资助金额:
    $ 166.98万
  • 项目类别:
Molecular and cellular characterization of essential human genes.
人类必需基因的分子和细胞特征。
  • 批准号:
    10708906
  • 财政年份:
    2022
  • 资助金额:
    $ 166.98万
  • 项目类别:
Molecular Characterization Trial of Irradiated Rectal Cancer
辐照直肠癌的分子表征试验
  • 批准号:
    10708055
  • 财政年份:
    2022
  • 资助金额:
    $ 166.98万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了